Literature DB >> 10835504

Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model.

S Kinuya1, K Yokoyama, S Konishi, T Hiramatsu, N Watanabe, N Shuke, T Aburano, T Takayama, T Michigishi, N Tonami.   

Abstract

We previously found that the efficacy of radioimmunotherapy (RIT) with (131)I-A7, an IgG(1) against M(r) 45000 glycoprotein on colon cancer, was enhanced by local hyperthermia (HT) or chemotherapy with 5-fluorouracil (5-FU). In this study, we aimed to further enhance its efficacy by combining these three modalities. Human colon cancer xenografts (146 x 12 mm(3)) in Balb / c nu / nu female mice were treated with 9.25 MBq (131)I-A7 i.v. combined with HT (43 degrees C for 1 h) and 5-FU (30 mg / kg / day i.p. for 5 days). Tumor growth delay, (Tq(treated) - Tq(control) )/ Tq(control) where Tq is tumor quadrupling time, in mice treated with RIT + HT + 5-FU was improved to 12.7 from 5.90, 7.55 and 10.1 with RIT alone, RIT + 5-FU and RIT + HT, respectively. Complete response was observed in 4 out of 8 tumors with RIT + HT + 5-FU and 3 out of 10 with RIT + HT. No tumor showed complete response with RIT + 5-FU or RIT alone. 5-FU slightly increased myelotoxicity of RIT, but HT did not affect it. Body weight loss was not enhanced by the combination. These results indicate that the combination of three modalities is a feasible approach to enhance the antitumor efficacy of RIT without serious increase of toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835504      PMCID: PMC5926375          DOI: 10.1111/j.1349-7006.2000.tb00983.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.

Authors:  H B Breitz; P L Weiden; J L Vanderheyden; J W Appelbaum; M J Bjorn; M F Fer; S B Wolf; B A Ratliff; C A Seiler; D C Foisie
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

2.  Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Authors:  T M Behr; R M Sharkey; M E Juweid; R M Dunn; R C Vagg; Z Ying; C H Zhang; L C Swayne; Y Vardi; J A Siegel; D M Goldenberg
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

3.  Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

Authors:  S J DeNardo; D L Kukis; L A Kroger; R T O'Donnell; K R Lamborn; L A Miers; D G DeNardo; C F Meares; G L DeNardo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.

Authors:  B B Mittal; M A Zimmer; V Sathiaseelan; A B Benson; R R Mittal; S Dutta; S T Rosen; S M Spies; J M Mettler; M W Groch
Journal:  Cancer       Date:  1996-11-01       Impact factor: 6.860

5.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

6.  Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts.

Authors:  S Kinuya; K Yokoyama; T Hiramatsu; H Tega; K Tanaka; S Konishi; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami
Journal:  Cancer Lett       Date:  1999-06-01       Impact factor: 8.679

7.  Alterations in tumor microvasculature during hyperthermia.

Authors:  H A Eddy
Journal:  Radiology       Date:  1980-11       Impact factor: 11.105

8.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

Authors:  O W Press; J F Eary; F R Appelbaum; P J Martin; W B Nelp; S Glenn; D R Fisher; B Porter; D C Matthews; T Gooley
Journal:  Lancet       Date:  1995-08-05       Impact factor: 79.321

9.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

10.  Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.

Authors:  S Kinuya; K Yokoyama; H Tega; T Hiramatsu; S Konishi; W Yamamoto; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami
Journal:  Jpn J Cancer Res       Date:  1998-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.